Health care biotech companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Biogen has the lowest figure of the 19 health care biotech companies ranked by P/S ratio, at 3.7, followed by Qiagen (4.9) and Neurocrine Biosciences (5.5). Figures as of 20 Nov 2026, 04:26 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 19
- Lowest
- Biogen3.7
- Median
- 14.3
- Combined market value
- SEK 8.44T
- Countries
- 5
- Not ranked
- 5no P/S ratio on file
Market values as of .
All countries▾
Health Care▾
Biotech▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 3.7 | SEK 372B | SEK 2,516.57 | 1.70% down | 49% up | ||
| 2 | QiagenQGEN · Health Care | 4.9 | SEK 104.4B | SEK 505.39 | 0.14% up | 9% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 5.5 | SEK 161.4B | SEK 1,594.59 | 3.85% down | 17% up | ||
| 4 | BioNTechBNTX · Health Care | 6.3 | SEK 205.5B | SEK 828.71 | 2.26% down | 14% down | ||
| 5 | AmgenAMGN · Health Care | 6.5 | SEK 2.42T | SEK 4,468.59 | 1.14% down | 32% up | ||
| 6 | ExelixisEXEL · Health Care | 6.9 | SEK 163.6B | SEK 670.36 | 3.60% down | 63% up | ||
| 7 | Gilead SciencesGILD · Health Care | 7.0 | SEK 2.1T | SEK 1,695.81 | 1.45% down | 35% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | 7.6 | SEK 108B | SEK 947.44 | 2.88% down | 39% up | ||
| 9 | Bio-TechneTECH · Health Care | 9.4 | SEK 116.3B | SEK 740.32 | 0.07% down | 24% up | ||
| 10 | argenxARGX · Health Care | 14.3 | SEK 603.3B | SEK 9,592.97 | 0.08% up | 2% up | ||
| 11 | RepligenRGEN · Health Care | 14.7 | SEK 110.8B | SEK 1,734.10 | 1.38% down | 12% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | 16.4 | SEK 46.2B | SEK 285.64 | 1.44% down | 74% up | ||
| 13 | Twist BioscienceTWST · Health Care | 20.2 | SEK 77.5B | SEK 1,136.65 | 4.07% down | 346% up | ||
| 14 | Krystal BiotechKRYS · Health Care | 24.1 | SEK 95.3B | SEK 3,216.06 | 0.15% up | 54% up | ||
| 15 | ModernaMRNA · Health Care | 41.5 | SEK 821.3B | SEK 2,029.82 | 1.29% up | 780% up | ||
| 16 | ImmunityBioIBRX · Health Care | 61.7 | SEK 71.2B | SEK 66.90 | 1.94% down | 232% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | 260 | SEK 103.8B | SEK 1,215.77 | 1.44% down | 87% up | ||
| 18 | CRISPR TherapeuticsCRSP · Health Care | 1076 | SEK 38.5B | SEK 396.43 | 3.14% down | 18% down | ||
| 19 | CG OncologyCGON · Health Care | 1811 | SEK 74.5B | SEK 834.00 | 2.38% up | 97% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 10.1832 SEK). 5 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which health care biotech companies have the lowest P/S ratio?
Biogen (3.7), Qiagen (4.9) and Neurocrine Biosciences (5.5) have the lowest P/S ratio of the 19 health care biotech companies ranked here as of 20 Nov 2026, 04:26 UTC.
How many health care biotech companies are in this ranking?
19 are ranked by P/S ratio. 5 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these health care biotech companies worth together?
The 19 health care biotech companies ranked by P/S ratio have a combined market value of SEK 8.44T as of 20 Nov 2026, 04:26 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Health care biotech companies by P/S ratio”, data as of 20 November 2026. https://funkfolio.com/companies/category/biotech?sector=health-care&by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.